In its annual World Preview 2020 report, EvaluatePharma, a pharmacy-focused data analytics firm, forecasted which prescription drugs will be best-sellers in 2026. Merck's oncology drug Keytruda is expected to top the list.
EvaluatePharma's 10 best-selling drugs in 2026 and their expected global sales:
- Keytruda (Merck) — $24.9 billion
- Opdivo (Bristol Myers Squibb) — $12.7 billion
- Eliquis (Bristol Myers Squibb) — $12.6 billion
- Biktarvy (Gilead) — $11.7 billion
- Imbruvica (AbbVie + Johnson & Johnson) — $10.7 billion
- Ibrance (Pfizer) — $9.7 billion
- Tagrisso (AstraZeneca) — $9.5 billion
- Dupixent (Sanofi) — $9.4 billion
- Trikafta (Vertex Pharmaceuticals) —$8.7 billion
- Ozempic (Novo Nordisk) — $8.3 billion